

**Supplementary Table 1--Demographics, Other Baseline and Pre-Exposure Characteristics Used in Analysis**

<b>Characteristics</b>
Age
Gender
Geographic region
Health plan type
Payer type
Prescribing physician specialty
Quarter of study entry (2005Q2 – 2009Q1)
Top 50 primary ICD-9 diagnosis codes for most recent hospitalization pre-exposure
Top 50 secondary ICD-9 diagnosis codes for most recent hospitalization pre-exposure
Top 50 procedures (inpatient or outpatient) pre-exposure
Top 50 ICD-9 diagnosis codes for recent physician visit (pre-exposure)
Top 50 medications (NDC) pre-exposure
Health services utilization during pre-exposure period <ul style="list-style-type: none"> <li>• Outpatient visits, outpatient specialist visits, emergency room (ER) visits, hospital admissions, total costs (inpatient, ER, outpatient, pharmacy)</li> </ul>
Charlson Comorbidity Index
Diabetes Severity Indicators:* <ul style="list-style-type: none"> <li>• Glucose-lowering agents used in pre-exposure period, diabetic retinopathy, diabetic retinopathy, peripheral neuropathy, renal impairment, dialysis</li> </ul>
Cardiovascular disease indicators:* <ul style="list-style-type: none"> <li>• Acute myocardial infarction, ischemic stroke, coronary revascularization procedure, CHF, ACS, DVT, Arrhythmia / conduction-related events, hyperlipidemia, hypertriglyceridemia, hypertension, ischemic heart disease</li> </ul>

\*Some of these may also be included in other characteristics (i.e., not mutually exclusive)

Supplementary Table 2--CV Endpoints and Codes Used in Primary Analysis

<b>Primary CV Endpoints</b>	
<b>Endpoints:</b>	<b>ICD-9-CM Codes (unless noted)</b>
Acute myocardial infarction	410.xx (excluding 410.7x)
Ischemic stroke	433.x1, 434.x1, 435.9, 436, 437.1x, 437.9x
Coronary revascularization procedures:	(CPT-4 codes)
Angioplasty/atherectomy	35450-35459, 35470-35475, 35480-35495
PTCA/stenting	92980, 92981, 92982, 92984, 92995, 92996, G0290, G0291, S2211, S2222
CABG	33510-33536, 33572, S2204-S2209

Supplementary Table 3--Medications, By Drug Class, and Generic Product Index Codes Included In Analysis

<b>Glucose-Lowering Agents</b>	
<b>Agents</b>	<b>Generic Product Index Code</b>
Exenatide	2717*
Insulins	2710*
Pramlintide	2715*
Sulfonylureas	2720*
Metformin	2725*
Non-sulfonylurea secretagogues (meglitinide analogues)	2728*
$\alpha$ -glucosidase inhibitors	2750*
Sitagliptin	2755*
TZDs	2760*
Sulfonylurea-Metformin	279970023*, 279970024*
TZD-Sulfonylurea	279978024*, 279978026*
TZD-Metformin	279980024*, 279980026*
Sitagliptin-Metformin	279925027*

**Supplementary Table 4--Other (Non-Glucose-Lowering Medications) and Codes Used in Analysis**

<i>Other Medications</i>	
<b>Drug Class</b>	<b>Generic Product Index Code(s)</b>
Antihypertensive agents	33* (beta blockers) 34* (calcium channel blockers) 36* (antihypertensives) 3610* (angiotensin-converting enzyme [ACE] inhibitors) 3615* (angiotensin-receptor blockers [ARBs]) 3640* (vasodilators) 37* (diuretics)
Antiarrhythmia agents	312000* (cardiotonics, cardiac glycosides) 35* (antiarrhythmias) J1160, J1742, J2001, J2690
Antihyperlipidemic agents	39* 3920* (fibrates) 3640* (HMG COA reductase inhibitors [statins])
Antiobesity agents	6125*
Antiplatelet agents	6410* (salicylates) 8515* (platelet aggregation inhibitors) J0130, J1327, J3246
Nonsteroidal anti-inflammatory drugs (NSAIDs)	6610*
Lipotropic agents	8040*
Anticoagulant or antithrombolytic-related agents	83* (anticoagulants / heparins) 84100010* (hemostatics) 85500010* (protamine) 8560* (thrombolytic enzymes) J1642, J1644, J1650, J3430, J2995, J3364, J3365, J2720
Immunomodulating medications	9939* (immunomodulators) 9940* (immunosuppressive therapy)